Serina Therapeutics’ Announces Close of $ 5 Million Financing to Advance SER-214 and Polymer Oncology Programs

Huntsville, AL, December 18th, 2014

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has closed a private round of financing for $ 5 million. The proceeds of the financing will be used to advance SER-214 – a once-per-week injection to treat Parkinson’s disease and restless leg syndrome – into Phase I in 2015.

“We are very pleased to announce the close of this round of financing. Our existing shareholders, and a group of new shareholders, have been instrumental in helping us advance our polymer technology steadily toward the clinic. We are excited that our first polymer conjugate will enter Phase I in the first half of 2015 and this financing assures us we will have the resources to do so.”

SER-214 is Serina’s most advanced polymer conjugate, with plans to enter a Phase I trial in Parkinson’s disease patients in the first half of 2015. It is a once-per-week injectable that can be delivered in a standard insulin syringe, and results in continuous drug delivery. Continuous dopaminergic stimulation, which would result from continuous drug delivery, has been a long-sought clinical strategy to ameliorate the sometimes disabling consequences of oral treatment with short-acting L-DOPA formulations and dopamine agonists.

Serina’s pipeline programs are aimed primarily at oncology indications that address significant unmet medical needs. Polymers of POZ can be targeted to specific receptors on the surface of cancer cells using either small molecules or antibodies, and this approach may provide a much wider therapeutic index when employing very potent toxins attached to the polymer. These programs were validated in proof-of-concept in cell lines in 2014, and will be evaluated in animal studies in 2015.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com